Senores Pharmaceuticals , a global research-driven pharmaceutical company, has reported robust financial results for the second quarter, showcasing significant growth across key metrics.

Financial Highlights

Senores Pharmaceuticals reported quarterly revenue of 1.62 billion rupees compared to 1.01 billion rupees in the same period last year, representing a year-over-year increase of 60.80%. The company's consolidated net profit surged to 330 million rupees, marking a substantial 131% increase from 130 million rupees in the same period last year. This impressive growth was accompanied by improved operational efficiency.

*bps: basis points

Segment Performance

Senores Pharmaceuticals' growth was primarily driven by its strong performance in regulated markets:

• Regulated Markets: Revenue grew by 86.9% year-on-year to 1,069 million rupees. The EBITDA margin for this segment improved from 36% to 44% on a sequential basis.

• Emerging Markets: While revenue stood at 317 million rupees, showing a slight decline, the company reported steady growth in margins on a sequential basis.

• Branded Generics: This segment witnessed significant growth, with revenues increasing more than tenfold year-on-year.

Operational Highlights

The company launched eight new products in regulated markets during the quarter, achieving better-than-expected sales. Senores Pharmaceuticals' portfolio expansion continues, with:

• 32 own commercial products
• 81 approved ANDA products
• 70 pipeline products
• 32 CDMO/CMO commercial products
• 45 CDMO/CMO pipeline products

In emerging markets, the company has 394 approved products and 824 products under registration, with a presence across more than 40 countries.

Management Commentary

Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, commented on the results: "We delivered a strong performance, with revenues rising 61% and profit after tax growing 131% year-on-year. In the Regulated Markets, we launched eight new products during the quarter, achieving better-than-expected sales. With additional launches and scale-up of existing products in the coming quarters, we expect this growth momentum in the Own Products business to continue."

Shah added, "Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on 4 key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets; and (iv) Scale-up of Branded Generics business in India."

Cash Flow and Future Outlook

Operating cash flows strengthened, rising over threefold to 310 million rupees in the first half of the fiscal year from 90 million rupees in the same period of the previous year. The company expects to maintain and build further on this trajectory going forward.

With its robust product pipeline, expanding global presence, and focus on high-margin segments, Senores Pharmaceuticals appears well-positioned to capitalize on growth opportunities in both regulated and emerging pharmaceutical markets.

Senores Pharmaceuticals Limited has announced a significant development for its material subsidiary, Havix Group Inc. (operating as Aavis Pharmaceuticals). The company has successfully addressed and resolved all observations identified during a recent US Food and Drug Administration (FDA) inspection, leading to the receipt of an Establishment Inspection Report (EIR) on November 4, 2025.

Inspection Details

The FDA conducted an inspection of Havix's manufacturing facility located in Hoschton, Georgia, from July 21-25, 2025. The inspection resulted in three minor observations under Form 483. These observations have since been addressed and resolved by Havix, demonstrating the company's commitment to maintaining high-quality standards in its pharmaceutical manufacturing processes.

Implications for Senores Pharmaceuticals

The receipt of the EIR from the FDA is a positive development for Senores Pharmaceuticals and its US subsidiary. It indicates that the FDA is satisfied with the corrective actions taken by Havix in response to the observations made during the inspection. This outcome is crucial for maintaining the company's ability to manufacture and distribute pharmaceutical products in the United States market.

Additional Corporate Development

In a separate but related development, Senores Pharmaceuticals has also announced a strategic move to expand its presence in the US market. The company's wholly-owned subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into a Limited Liability Company Agreement (LLCA) dated November 04, 2025. Through this agreement, SPI has subscribed to 51% of the membership interest in Zoraya Pharmaceuticals, LLC, a newly formed entity in Delaware, USA.

Key Details of the New Subsidiary

This strategic move transforms Zoraya Pharmaceuticals, LLC into a step-down subsidiary of Senores Pharmaceuticals Limited, potentially strengthening the company's foothold in the US pharmaceutical market.

These developments collectively underscore Senores Pharmaceuticals' commitment to expanding its operations and maintaining regulatory compliance in the highly regulated US pharmaceutical market. The successful resolution of FDA observations and the formation of a new subsidiary may position the company for potential growth opportunities in the future.